Related Experiment Videos
Growth hormone secretion in Prader-Willi syndrome
Journal of Endocrinological Investigation
|October 10, 1998
Summary
Prader-Willi Syndrome (PWS) patients may have distinct endocrine profiles. Some PWS patients exhibit low growth hormone (GH) and IGF-1 levels, suggesting potential benefits from GH therapy.
Area of Science:
- Pediatric Endocrinology
- Genetics
- Metabolic Disorders
Background:
- Prader-Willi Syndrome (PWS) is a genetic disorder causing obesity, hypogenitalism, and short stature.
- Previous studies indicate low growth hormone (GH) serum levels in PWS patients, linked to hypothalamic-pituitary dysfunction.
Purpose of the Study:
- To investigate spontaneous nocturnal GH secretion and GH response to provocative tests in PWS patients.
- To identify potential endocrinological subgroups within PWS.
Main Methods:
- Studied five patients with Prader-Willi Syndrome.
- Assessed spontaneous nocturnal GH secretion.
- Evaluated GH response to provocative tests.
- Measured serum GH and IGF-1 levels.
- Monitored thyroid function.
Main Results:
- Three patients (Group A) showed abnormally low GH and IGF-1 serum levels.
- Two patients (Group B) exhibited normal GH secretion and IGF-1 levels.
- No thyroid dysfunction was detected in any patient.
Conclusions:
- Findings suggest two potential endocrinological subgroups in PWS patients.
- One subgroup may have deficient GH secretion, while the other appears normal.
- Further studies are needed to confirm these subgroups and identify PWS patients eligible for recombinant GH therapy.